AKT1 and neoplasm: Nevertheless, a preclinical study indicated a benefit from Ad-IL-24 and erlotinib in terms of tumor growth inhibition and induction of apoptosis through Apaf-1 and AKT signaling pathway inhibition (Table 6) [119].